Literature DB >> 32164265

Inflammatory Mechanisms of HCC Development.

Maria Grazia Refolo1, Caterina Messa1, Vito Guerra2, Brian Irving Carr3, Rosalba D'Alessandro1.   

Abstract

HCC (hepatocellular carcinoma) is the second leading cause of cancer deaths worldwide, with several etiologic causes, mostly inflammation-associated. Different inflammatory responses in the liver can be triggered by different etiological agents. The inflammatory process can be resolved or be persistent, depending on the etiology and multiple other factors. Chronic inflammation, tissue remodeling, genetic alterations, and modifications in cellular signaling are considered to be key processes promoting immunosuppression. The progressive immunosuppression leads to the inactivation of anti-tumor immunity involved in HCC carcinogenesis and progression. Tumor cellular processes including DNA damage, necrosis, and ER (endoplasmic reticulum) stress can affect both immune-surveillance and cancer-promoting inflammation, supporting a mutual interdependence. Here, we review the current understanding of how chronic liver injury and inflammation is triggered and sustained, and how inflammation is linked to HCC. The identification of many hepatic microenvironmental inflammatory processes and their effector molecules, has resulted in extensive translational work and promising clinical trials of new immunomodulatory agents.

Entities:  

Keywords:  HCC; cancer etiology; chronic inflammation; immunosuppression; immunosurveillance

Year:  2020        PMID: 32164265     DOI: 10.3390/cancers12030641

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  36 in total

1.  Heterogeneous phenotypes of Pten-null hepatocellular carcinoma in hepatitis B virus transgenic mice parallels liver lobule zonal gene expression patterns.

Authors:  Claudia E Oropeza; Caitlin R Ondracek; Grant Tarnow; Mark Maienschein-Cline; Stefan J Green; Alan McLachlan
Journal:  Virology       Date:  2021-11-23       Impact factor: 3.616

2.  Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma.

Authors:  Brian I Carr; Vito Guerra; Rossella Donghia; Seai Yilmaz
Journal:  J Gastrointest Cancer       Date:  2021-10-06

3.  Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures.

Authors:  Soumyadeep Mukherjee; Arpita Kar; Najma Khatun; Puja Datta; Avik Biswas; Subhasis Barik
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

4.  Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1.

Authors:  Dandan Lin; Yu Mei; Lei Lei; Zuhairah Binte Hanafi; Ziqi Jin; Yonghao Liu; Yuan Song; Yinsheng Zhang; Bo Hu; Chunliang Liu; Jinhua Lu; Haiyan Liu
Journal:  Oncoimmunology       Date:  2022-06-15       Impact factor: 7.723

Review 5.  Dysregulation of immune checkpoint proteins in hepatocellular carcinoma: Impact on metabolic reprogramming.

Authors:  Kanchan Vishnoi; Sandeep Kumar; Rong Ke; Ajay Rana; Basabi Rana
Journal:  Curr Opin Pharmacol       Date:  2022-05-05       Impact factor: 4.768

6.  Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.

Authors:  Hikmet Akkiz; Brian I Carr; Harika G Bag; Ümit Karaoğullarından; Kendal Yalçın; Nazim Ekin; Ayşegül Özakyol; Engin Altıntaş; Hatice Y Balaban; Halis Şimşek; Ahmet Uyanıkoğlu; Ayhan Balkan; Sedef Kuran; Oğuz Üsküdar; Yakup Ülger; Burak Güney; Anil Delik
Journal:  Int J Clin Pract       Date:  2020-12-12       Impact factor: 2.503

7.  CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.

Authors:  Brian I Carr; Volkan Ince; Harika Gozukara Bag; Sertac Usta; Veysel Ersan; Burak Isik; Sezai Yilmaz
Journal:  Clin Pract (Lond)       Date:  2021

8.  The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.

Authors:  Minah Kim; Yeonju Lee; Jun Sik Yoon; Minjong Lee; So Shin Kye; Sun Woong Kim; Yuri Cho
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

9.  Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?

Authors:  Lukas Müller; Felix Hahn; Aline Mähringer-Kunz; Fabian Stoehr; Simon J Gairing; Friedrich Foerster; Arndt Weinmann; Peter R Galle; Jens Mittler; Daniel Pinto Dos Santos; Michael B Pitton; Christoph Düber; Roman Kloeckner
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 10.  The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma.

Authors:  Bart Vanderborght; Sander Lefere; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Cells       Date:  2020-10-30       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.